ClinicalTrials.gg
CompletedNCT03267316CANFOURUpdated Aug 22, 2024

A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors

A Phase 1/2 interventional study of CAN04 and Cisplatin in Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma and Triple Negative Breast Cancer, sponsored by Cantargia AB. Completed at 25 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-22.

Sponsored by Cantargia AB · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
167
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 148 studies in Carcinoma, Non-Small-Cell Lung with a site in Denmark — 32 open to participants now, 55 under way, 19 of them phase 3. Carcinoma, Non-Small-Cell Lung · Denmark.

Enrollment
79th of 132
167 · median 249
Started
2017
with 8 others
Phase 1/2
24 of 148
5 open now
Registered
75th of 148
by date

Among the 148 studies in Carcinoma, Non-Small-Cell Lung with a site in Denmark, this one is the 79th largest by enrollment of the 132 interventional ones that give a count, is one of 9 that started in 2017, is one of 24 in phase 1/2, and was the 75th registered.

Carcinoma, Non-Small-Cell Lung

7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

32 of the 148 studies in Carcinoma, Non-Small-Cell Lung with a site in Denmark are open now. Recruiting first, the newest first:

27 more — sign in →

All 32 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 148 studies in Carcinoma, Non-Small-Cell Lung with a site in Denmark, or all of them as a file.
02

Study summary

This study will evaluate the safety, tolerability, and preliminary antitumor activity of CAN04 both as a monotherapy and in combination with standard of care treatment in subjects with solid cancer tumors.

Following completion of the first part, the dose escalation cohorts, and determination of maximum tolerated dose or recommended phase 2 dose (MTD/RP2D), safety and tolerability will be further evaluated in an expanded cohort of subjects with pancreatic or lung cancer, as monotherapy or in combination with the standard of care treatment and to identify the RP2D of CAN04 in combination with standard of care. In addition, early signs of efficacy during treatment with CAN04 will be investigated.

Read the detailed description

CAN04 is a first-in-class fully humanized and ADCC enhanced monoclonal antibody, targeting the Interleukin 1 Receptor Accessory Protein (IL1RAP).

The CAN04 strategy is to attack the IL1RAP target molecule using an effective antibody-based cancer treatment. In preclinical (in vitro and in vivo) studies, CAN04 has shown two distinct mechanisms of action:

  1. By blocking the intracellular signals from the IL1RAP target molecule, thereby impairing the cancer cells' ability to secrete tumor stimulating cytokines, in turn reducing tumor inflammation and tumor progression.
  2. Through antibody dependent cellular cytotoxicity (ADCC) against IL1RAP expressing tumor cells where CAN04 stimulates natural killer (NK) cells to attack the tumor cells.

The study is a combined phase 1/2a, open-label, dose-escalation followed by dose expansion, safety and tolerability clinical trial, in patients with relapsed or refractory solid tumors. It consists of two parts.

In Part I (Dose Escalation - DE), the intention is to include patients with any of the four solid tumor types: Non-Small Cell Lung Cancer (NSCLC), Pancreatic Ductal Adenocarcinoma (PDAC), Triple Negative Breast Cancer (TNBC) or Colorectal Cancer (CRC). In this part of the study safety and tolerability will be documented and the MTD/ RP2D will be determined. Patients will stay on CAN04 treatment until disease progression, unacceptable toxicity, or discontinuation for any other reason. [Completed December 2018]

In Part II (Expansion Cohort - EC), safety and tolerability will be further evaluated in an expanded cohort of subjects with PDAC or NSCLC to identify RP2D of CAN04 in combination with standard of care. In addition, early signs of efficacy during treatment with CAN04 will be investigated, as monotherapy or in combination with the standard of care.

Patients will stay on treatment until disease progression, unacceptable toxicity, or discontinuation for any other reason. [Enrollment to all arms completed]

03

Conditions studied

  • Non Small Cell Lung Cancer
  • Pancreatic Ductal Adenocarcinoma
  • Triple Negative Breast Cancer
  • Colorectal Cancer

Keywords

  • First-in-Human
  • Phase 1
  • Phase 2
  • Antibody, Monoclonal
  • IL1RAP
  • Safety
  • Tolerability
  • Cancer
  • Solid tumor
  • Malignant
  • Dose escalation
  • Dose expansion
  • CAN04
  • Immunoglobulin
  • Clinical Trial
  • Infusion
  • Antineoplastic
  • Anticancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 year.
  2. in accordance to by computed tomography (CT) or magnetic resonance imaging (MRI) scan, no more than 6 weeks prior to screening.
  3. At least 4 weeks since the last dose of radiation therapy, immunotherapy, or surgery; at least 6 weeks for therapy which is known to have delayed toxicity; at least 4 weeks since treatment with biologic/targeted therapies.
  4. (ECOG) performance status ≤1.
  5. or cytologically confirmed diagnosis of unresectable stage III or stage IV squamous or non-squamous NSCLC (applicable Part II, Combination - NSCLC (NCG) arm only).

    • Subjects must be eligible to receive standard chemotherapy regimen with cisplatin/gemcitabine or a second line standard chemotherapy regimen with cisplatin/gemcitabine after relapsing from first line with pembrolizumab monotherapy.
    • Subjects with actionable mutations (EGFR, ALK, ROS) can be enrolled if they have previously progressed to all approved standard of care targeted therapies and the next line of standard therapy is a platinum doublet.
  6. Histologically or cytologically confirmed diagnosis of unresectable stage III or stage IV non-squamous NSCLC (applicable Part II, Combination - non-squamous NSCLC NCP arm only).

    • Subjects must be eligible to receive first line standard chemotherapy regimen with carboplatin/pemetrexed or a second line standard chemotherapy regimen with carboplatin/pemetrexed after relapsing from first line with pembrolizumab monotherapy.
    • Subjects with actionable mutations (EGFR, ALK, ROS) can be enrolled if they have previously progressed to all approved standard of care targeted therapies and the next line of standard therapy is a platinum doublet.
  7. Newly diagnosed, treatment naїve, histologically confirmed, unresectable, locally advanced or (stage III or stage IV) PDAC (applicable Part II, Combination - PDAC arms only).

    • Subjects must be eligible to receive treatment with nab-paclitaxel and gemcitabine.

Exclusion criteria

Exclusion Criteria:

  1. Subjects receiving , etanercept or other TNF-α inhibitors or any other agents during or just prior to (within 28 days of first study drug administration) participation in this study.
  2. Clinical evidence of an active second .
  3. Subjects with a \<12 weeks.
  4. Uncontrolled or significant cardiovascular disease defined as Classification III, or IV.
  5. subject currently receiving systemic therapy.
  6. Other medical conditions that in the opinion of the investigator disqualify the subject for inclusion.
  7. Applicable Part II, Combination - NSCLC (NCG and NCP) arms only

    • with anti-cancer medication other than pembrolizumab administered as 1st line.
    • Known tumor EGFR mutation, unless to EGFR-directed therapy or if the subject has progressed to all approved anti-EGFR therapies.
    • Known tumor ALK rearrangements, unless contraindication to ALK-directed therapy or ALK-directed therapy not available or if the subject has progressed to all approved anti-EGFR therapies.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

iRECIST and mRECIST

Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
167 participants (actual)

Study arms

  • Experimental
    Dose escalation

    Cohorts of 3 subjects will receive once weekly (Q1W) treatment with CAN04. The Dose Limiting Toxicity (DLT) observation period for each dose level will be the first 21 days of treatment with CAN04. \[Completed December 2018\]

    Biological: CAN04

  • Experimental
    Monotherapy (Q1W)

    Subjects with either PDAC or NSCLC, will receive treatment with CAN04 monotherapy once weekly (Q1W).

    Biological: CAN04

  • Experimental
    Monotherapy (Q1W/Q2W)

    Subjects with either PDAC or NSCLC, will receive treatment with CAN04 monotherapy once weekly (Q1W) for the first 6 weeks followed by treatment every second week (Q2W).

    Biological: CAN04

  • Experimental
    Combination - NSCLC (NCG)

    Subjects with NSCLC will receive treatment with CAN04 once weekly (Q1W) for the first 6 weeks followed by treatment every second week (Q2W) in combination with standard-of-care therapy (cisplatin/gemcitabine).

    Biological: CAN04 · Drug: Cisplatin · Drug: Gemcitabine

  • Experimental
    Combination - PDAC

    Subjects with PDAC will receive treatment with CAN04 once weekly (Q1W) for the first 6 weeks followed by treatment every second week (Q2W) in combination with standard-of-care therapy (nab-paclitaxel/gemcitabine).

    Biological: CAN04 · Drug: Gemcitabine · Drug: Nab-paclitaxel

  • Experimental
    Combination - PDAC (1 mg/kg)

    Subjects with PDAC will receive CAN04 on Day 1 and 15 in cycles of 28 days in combination with standard-of-care therapy (nab-paclitaxel/gemcitabine). During first cycle CAN04 also to be administered on Day 8.

    Biological: CAN04 · Drug: Gemcitabine · Drug: Nab-paclitaxel

  • Experimental
    Combination - PDAC (2,5 mg/kg)

    Subjects with PDAC will receive CAN04 on Day 1 and 15 in cycles of 28 days in combination with standard-of-care therapy (nab-paclitaxel/gemcitabine). During first cycle CAN04 also to be administered on Day 8.

    Biological: CAN04 · Drug: Gemcitabine · Drug: Nab-paclitaxel

  • Experimental
    Combination - non-squamous NSCLC (NCP)

    Subjects with non-squamous NSCLC will receive CAN04 on Day 1 and 8 in cycles of 21 days in combination with standard-of-care therapy (carboplatin/pemetrexed).

    Biological: CAN04 · Drug: Carboplatin · Drug: Pemetrexed

Interventions

  • BiologicalCAN04

    A fully humanized monoclonal immunoglobulin G1 (IgG1) antibody (hmAb) in aqueous solution administered by i.v. infusion.

  • Standard of care treatment

  • Standard of care treatment

  • Standard of care treatment

  • Standard of care treatment

  • Standard of care treatment

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)

    The incidence of Grade 3 or higher adverse events (AEs) related to CAN04 administration and according to the National Cancer Institute - Common Terminology Criteria for Adverse Events (CTCAE, version 4.03).

    Time frame: From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever occurs first

Secondary outcomes

  1. Maximum concentration (Cmax)

    Maximum plasma concentration of CAN04

    Time frame: 5 weeks

  2. Terminal half-life (t1/2)

    Terminal half-life of CAN04

    Time frame: 5 weeks

  3. Clearance (CL)

    Plasma clearance of CAN04

    Time frame: 5 weeks

  4. Apparent volume of distribution during the terminal phase (VZ)

    Apparent volume of distribution of CAN04 during the terminal phase

    Time frame: 5 weeks

  5. Area under the curve from time 0 to infinity (AUC0-∞)

    Area under the plasma concentration curve from time 0 to infinity

    Time frame: 5 weeks

  6. Anti-drug antibodies (ADA) against CAN04

    Immunogenicity of CAN04 after repeated administrations, assessed by ADA titers in serum.

    Time frame: Through study completion, an average of 6 months

  7. Preliminary signs of efficacy as assessed by tumor response

    Tumor response (irRC Part I Part II Monotherapy arms; iRECIST Part II Combination arms)

    Time frame: One year

07

Study locations

25 sites
  • Landeskrankenhaus Salzburg
    Salzburg, 5020, Austria
  • Medizinische Universität Wien
    Vienna, A-1090, Austria
  • Institut Jules Bordet
    Brussels, 1000, Belgium
  • University Hospital Gasthuisberg
    Leuven, 3000, Belgium
  • CHU de Liège
    Liège, B-4000, Belgium
  • Aalborg University Hospital
    Aalborg, 9000, Denmark
  • Rigshospitalet, Department of Oncology
    Copenhagen, 2100, Denmark
  • Herlev og Gentofte Hospital
    Herlev, 2730, Denmark
  • Odense University Hospital
    Odense, 5000, Denmark
  • East Tallinn Central Hospital
    Tallinn, 11312, Estonia
  • Tartu University Hospital
    Tartu, 50406, Estonia
  • Charité Universitätsmedizin Berlin
    Berlin, 10117, Germany
  • Asklepios Klinik Altona
    Hamburg, 227 63, Germany
  • Universitätsklinikum Ulm
    Ulm, 89081, Germany
  • Pauls Stradiņš Clinical University Hospital
    Riga, 1002, Latvia
  • Riga East Clinical University Hospital
    Riga, 1079, Latvia
  • The Hospital of Lithuanian University of Health Sciences
    Kaunas, 50161, Lithuania
  • National Cancer Institute
    Vilnius, 08660, Lithuania
  • Netherlands Cancer Institute
    Amsterdam, 1066 CX, Netherlands
  • Erasmus University Medical Center, Department of Medical Oncology
    Rotterdam, 3015 CE, Netherlands
  • Oslo University Hospital, Radiumhospitalet
    Oslo, 0379, Norway
  • Hospital 12 de Octubre
    Madrid, 28041, Spain
  • Hospital Universitario Quirónsalud Madrid
    Madrid, 28223, Spain
  • Hospital Universitario Central de Asturias
    Oviedo, 33011, Spain
  • Karolinska University Hospital
    Stockholm, 171 64, Sweden
08

References and documents

Publications

  • Robbrecht D, Jungels C, Sorensen MM, Spanggaard I, Eskens F, Fretland SO, Guren TK, Aftimos P, Liberg D, Svedman C, Thorsson L, Steeghs N, Awada A. First-in-human phase 1 dose-escalation study of CAN04, a first-in-class interleukin-1 receptor accessory protein (IL1RAP) antibody in patients with solid tumours. Br J Cancer. 2022 Apr;126(7):1010-1017. doi: 10.1038/s41416-021-01657-7. Epub 2021 Dec 13. PubMed 34903842 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2017 to primary completion in Mar 2024, 77 months.

Of 311 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's 77 months is above that.

Counting every sponsor, half of 434 studies reached it within 62 months; a quarter within 41 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2017
First posted
Aug 30, 2017
StartActual
Sep 19, 2017
Primary completionActual
Mar 14, 2024
CompletionActual
Mar 14, 2024
Last update
Aug 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03267316
Lead sponsor
Cantargia AB
Responsible party
Sponsor
First posted
Aug 30, 2017
Start date
Sep 19, 2017
Primary completion
Mar 14, 2024
Completion
Mar 14, 2024
Last update
Aug 22, 2024

Study contacts

Ahmad Awada, Professor
principal investigator · Jules Bordet Institute, Brussels, Belgium

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nidanilimab

Start the discussion